CymaBay Therapeutics to Participate in Upcoming Investment Conferences
Get Alerts CBAY Hot Sheet
Join SI Premium – FREE
NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY, Raymond James & Associates’ 45th Annual Institutional Investors Conference, March 4-6, in Orlando, Florida, and Leerink Partners Global Biopharma Conference, March 11-13, in Miami, Florida.
| Guggenheim Healthcare Talks 6th Annual Biotechnology Conference | ||
| Date: | Wednesday, February 7th, 2024 | |
| Time: | 1:00pm Eastern Time, Fireside Chat | |
| Webcast: | http://ir.cymabay.com/events | |
| Raymond James & Associates’ 45th Annual Institutional Investors Conference | ||
| Date: | Tuesday, March 5th, 2024 | |
| Time: | 2:50pm Eastern Time, Fireside Chat | |
| Webcast: | http://ir.cymabay.com/events | |
| Leerink Partners Global Biopharma Conference | ||
| Date: | Tuesday, March 12th, 2024 | |
| Time: | 11:20am Eastern Time, Fireside Chat | |
| Webcast: | http://ir.cymabay.com/events | |
About CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), Priority Medicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class investigational treatment for people with PBC. A new drug application for seladelpar was submitted to the FDA in December 2023. Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families, and communities we serve. To learn more, visit www.cymabay.com and follow us on X (formerly Twitter) and LinkedIn.
For additional information about CymaBay visit www.cymabay.com.
Public Relations Contact:
Theresa DolgeEvoke Kyne(609) 915-2156 [email protected]
Investor Relations Contact:
PJ KelleherLifeSci Advisors, LLC(617) 430-7579[email protected]
Source: CymaBay Therapeutics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Globex Reports that Royalty Partner Radisson is Commencing an Advanced Underground Exploration Project at the O’Brien Project Where Globex Owns Two Royalties
- U.S. Postal Service Will be Closed in Observance of Labor Day, September 7
- MicroStar Logistics Signs The Lagunitas Brewing Company to Keg Management Program
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Raymond James, Twitter, Guggenheim, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share